VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | LNP023 for paroxysmal nocturnal hemoglobinuria

Régis Peffault de Latour, MD, PhD, Saint-Louis Hospital, Paris, France, discusses the results of a study (NCT03439839) evaluating the safety and efficacy of LNP023, a factor B inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PHN) in combination with standard treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter